Wockhardt Limited (BSE: WOCKPHARMA.BO) Stock Competitors & Peer Comparison

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SUNPHARMA.NS has a market cap of 4.7T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SUNPHARMA.NS trades at ₹1,987.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SUNPHARMA.NS's P/E ratio is 38.34. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SUNPHARMA.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SUNPHARMA.BO has a market cap of 4.7T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SUNPHARMA.BO trades at ₹1,983.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SUNPHARMA.BO's P/E ratio is 38.70. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SUNPHARMA.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, DIVISLAB.BO has a market cap of 2T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while DIVISLAB.BO trades at ₹7,445.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas DIVISLAB.BO's P/E ratio is 73.31. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to DIVISLAB.BO's ROE of +0.16%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check DIVISLAB.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, DIVISLAB.NS has a market cap of 2T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while DIVISLAB.NS trades at ₹7,434.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas DIVISLAB.NS's P/E ratio is 76.35. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to DIVISLAB.NS's ROE of +0.16%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check DIVISLAB.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, TORNTPHARM.NS has a market cap of 1.9T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while TORNTPHARM.NS trades at ₹4,923.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas TORNTPHARM.NS's P/E ratio is 75.21. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to TORNTPHARM.NS's ROE of +0.26%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to TORNTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check TORNTPHARM.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, TORNTPHARM.BO has a market cap of 1.7T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while TORNTPHARM.BO trades at ₹4,920.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas TORNTPHARM.BO's P/E ratio is 76.13. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to TORNTPHARM.BO's ROE of +0.26%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to TORNTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check TORNTPHARM.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ZYDUSLIFE.NS trades at ₹1,110.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ZYDUSLIFE.NS's P/E ratio is 23.03. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ZYDUSLIFE.NS's ROE of +0.19%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ZYDUSLIFE.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ZYDUSLIFE.BO trades at ₹1,116.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ZYDUSLIFE.BO's P/E ratio is 23.11. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ZYDUSLIFE.BO's ROE of +0.19%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ZYDUSLIFE.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while LUPIN.BO trades at ₹2,400.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas LUPIN.BO's P/E ratio is 18.92. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check LUPIN.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while LUPIN.NS trades at ₹2,399.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas LUPIN.NS's P/E ratio is 18.92. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check LUPIN.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, MANKIND.NS has a market cap of 1.1T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while MANKIND.NS trades at ₹2,582.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas MANKIND.NS's P/E ratio is 51.65. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to MANKIND.NS's ROE of +0.12%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to MANKIND.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check MANKIND.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, MANKIND.BO has a market cap of 1.1T. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while MANKIND.BO trades at ₹2,597.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas MANKIND.BO's P/E ratio is 51.98. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to MANKIND.BO's ROE of +0.12%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to MANKIND.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check MANKIND.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, DRREDDY.NS has a market cap of 958.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while DRREDDY.NS trades at ₹1,141.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas DRREDDY.NS's P/E ratio is 22.38. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to DRREDDY.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check DRREDDY.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, DRREDDY.BO has a market cap of 957.6B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while DRREDDY.BO trades at ₹1,145.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas DRREDDY.BO's P/E ratio is 22.38. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to DRREDDY.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check DRREDDY.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, LAURUSLABS.BO has a market cap of 931.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while LAURUSLABS.BO trades at ₹1,733.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas LAURUSLABS.BO's P/E ratio is 103.71. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to LAURUSLABS.BO's ROE of +0.22%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to LAURUSLABS.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check LAURUSLABS.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, LAURUSLABS.NS has a market cap of 925.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while LAURUSLABS.NS trades at ₹1,740.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas LAURUSLABS.NS's P/E ratio is 104.09. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to LAURUSLABS.NS's ROE of +0.22%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to LAURUSLABS.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check LAURUSLABS.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, AUROPHARMA.NS has a market cap of 891.5B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while AUROPHARMA.NS trades at ₹1,546.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas AUROPHARMA.NS's P/E ratio is 25.68. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check AUROPHARMA.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, AUROPHARMA.BO has a market cap of 890.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while AUROPHARMA.BO trades at ₹1,548.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas AUROPHARMA.BO's P/E ratio is 25.67. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check AUROPHARMA.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ALKEM.NS has a market cap of 671.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ALKEM.NS trades at ₹5,623.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ALKEM.NS's P/E ratio is 34.56. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ALKEM.NS's ROE of +0.17%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ALKEM.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ALKEM.BO has a market cap of 671B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ALKEM.BO trades at ₹5,623.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ALKEM.BO's P/E ratio is 29.15. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ALKEM.BO's ROE of +0.17%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ALKEM.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, GLENMARK.NS has a market cap of 619.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while GLENMARK.NS trades at ₹2,201.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas GLENMARK.NS's P/E ratio is 35.99. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to GLENMARK.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check GLENMARK.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, GLENMARK.BO has a market cap of 618.9B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while GLENMARK.BO trades at ₹2,199.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas GLENMARK.BO's P/E ratio is 45.49. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check GLENMARK.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, IPCALAB.NS has a market cap of 451B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while IPCALAB.NS trades at ₹1,772.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas IPCALAB.NS's P/E ratio is 38.43. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to IPCALAB.NS's ROE of +0.14%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check IPCALAB.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, IPCALAB.BO has a market cap of 450.9B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while IPCALAB.BO trades at ₹1,781.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas IPCALAB.BO's P/E ratio is 49.56. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to IPCALAB.BO's ROE of +0.14%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check IPCALAB.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, AJANTPHARM.BO has a market cap of 423.2B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while AJANTPHARM.BO trades at ₹3,363.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas AJANTPHARM.BO's P/E ratio is 40.08. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to AJANTPHARM.BO's ROE of +0.25%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to AJANTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check AJANTPHARM.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, AJANTPHARM.NS has a market cap of 423B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while AJANTPHARM.NS trades at ₹3,350.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas AJANTPHARM.NS's P/E ratio is 40.10. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to AJANTPHARM.NS's ROE of +0.25%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to AJANTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check AJANTPHARM.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SUVENPHAR.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SUVENPHAR.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while JBCHEPHARM.NS trades at ₹2,416.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check JBCHEPHARM.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, JBCHEPHARM.BO has a market cap of 386.8B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while JBCHEPHARM.BO trades at ₹2,412.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas JBCHEPHARM.BO's P/E ratio is 52.61. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check JBCHEPHARM.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, EMCURE.NS has a market cap of 365.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while EMCURE.NS trades at ₹1,945.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas EMCURE.NS's P/E ratio is 72.63. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to EMCURE.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check EMCURE.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, PPLPHARMA.BO has a market cap of 255B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while PPLPHARMA.BO trades at ₹188.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas PPLPHARMA.BO's P/E ratio is -163.99. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to PPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check PPLPHARMA.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check PEL.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, PPLPHARMA.NS has a market cap of 254.8B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while PPLPHARMA.NS trades at ₹188.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas PPLPHARMA.NS's P/E ratio is -163.99. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to PPLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check PPLPHARMA.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, NEULANDLAB.NS has a market cap of 243.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while NEULANDLAB.NS trades at ₹18,868.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas NEULANDLAB.NS's P/E ratio is 63.33. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to NEULANDLAB.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check NEULANDLAB.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, NEULANDLAB.BO has a market cap of 243.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while NEULANDLAB.BO trades at ₹18,847.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas NEULANDLAB.BO's P/E ratio is 65.64. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to NEULANDLAB.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check NEULANDLAB.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, GRANULES.NS has a market cap of 208.8B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while GRANULES.NS trades at ₹840.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas GRANULES.NS's P/E ratio is 33.93. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to GRANULES.NS's ROE of +0.16%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to GRANULES.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check GRANULES.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, GRANULES.BO has a market cap of 208.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while GRANULES.BO trades at ₹839.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas GRANULES.BO's P/E ratio is 33.91. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to GRANULES.BO's ROE of +0.16%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to GRANULES.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check GRANULES.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ASTRAZEN.BO has a market cap of 204.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ASTRAZEN.BO trades at ₹8,110.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ASTRAZEN.BO's P/E ratio is 108.89. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ASTRAZEN.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ASTRAZEN.NS has a market cap of 204.2B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ASTRAZEN.NS trades at ₹8,111.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ASTRAZEN.NS's P/E ratio is 108.89. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ASTRAZEN.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, CAPLIPOINT.BO has a market cap of 199.6B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while CAPLIPOINT.BO trades at ₹2,626.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas CAPLIPOINT.BO's P/E ratio is 34.91. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to CAPLIPOINT.BO's ROE of +0.20%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to CAPLIPOINT.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check CAPLIPOINT.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, CAPLIPOINT.NS has a market cap of 199.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while CAPLIPOINT.NS trades at ₹2,624.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas CAPLIPOINT.NS's P/E ratio is 30.80. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to CAPLIPOINT.NS's ROE of +0.20%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to CAPLIPOINT.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check CAPLIPOINT.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ERIS.NS has a market cap of 194.5B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ERIS.NS trades at ₹1,385.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ERIS.NS's P/E ratio is 39.70. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ERIS.NS's ROE of +0.18%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to ERIS.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ERIS.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ERIS.BO has a market cap of 194.2B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ERIS.BO trades at ₹1,392.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ERIS.BO's P/E ratio is 45.39. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ERIS.BO's ROE of +0.18%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to ERIS.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ERIS.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, NATCOPHARM.BO has a market cap of 166.2B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while NATCOPHARM.BO trades at ₹926.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas NATCOPHARM.BO's P/E ratio is 12.51. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to NATCOPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check NATCOPHARM.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, NATCOPHARM.NS has a market cap of 166.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while NATCOPHARM.NS trades at ₹925.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas NATCOPHARM.NS's P/E ratio is 12.53. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to NATCOPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check NATCOPHARM.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, COHANCE.BO has a market cap of 164.2B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while COHANCE.BO trades at ₹429.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas COHANCE.BO's P/E ratio is 84.86. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to COHANCE.BO's ROE of +0.05%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to COHANCE.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check COHANCE.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, COHANCE.NS has a market cap of 163.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while COHANCE.NS trades at ₹428.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas COHANCE.NS's P/E ratio is 79.63. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to COHANCE.NS's ROE of +0.05%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to COHANCE.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check COHANCE.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, APLLTD.NS has a market cap of 160.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while APLLTD.NS trades at ₹819.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas APLLTD.NS's P/E ratio is 21.72. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to APLLTD.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check APLLTD.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, APLLTD.BO has a market cap of 160.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while APLLTD.BO trades at ₹819.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas APLLTD.BO's P/E ratio is 21.72. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check APLLTD.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, JUBLPHARMA.NS has a market cap of 155.2B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while JUBLPHARMA.NS trades at ₹964.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas JUBLPHARMA.NS's P/E ratio is 36.15. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to JUBLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check JUBLPHARMA.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, JUBLPHARMA.BO has a market cap of 155.2B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while JUBLPHARMA.BO trades at ₹969.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas JUBLPHARMA.BO's P/E ratio is 36.10. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to JUBLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check JUBLPHARMA.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ALIVUS.NS has a market cap of 139B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ALIVUS.NS trades at ₹1,123.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ALIVUS.NS's P/E ratio is 42.18. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to ALIVUS.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ALIVUS.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ALIVUS.BO has a market cap of 138.8B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ALIVUS.BO trades at ₹1,128.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ALIVUS.BO's P/E ratio is 25.15. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ALIVUS.BO's ROE of +0.05%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to ALIVUS.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ALIVUS.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check GLS.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to GLS.BO's ROE of +0.21%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check GLS.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SHILPAMED.NS has a market cap of 121.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SHILPAMED.NS trades at ₹608.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SHILPAMED.NS's P/E ratio is 47.92. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SHILPAMED.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SHILPAMED.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, VIYASH.NS has a market cap of 113.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while VIYASH.NS trades at ₹256.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas VIYASH.NS's P/E ratio is 80.65. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to VIYASH.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check VIYASH.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, PGHL.NS has a market cap of 112.6B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while PGHL.NS trades at ₹6,783.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas PGHL.NS's P/E ratio is 34.46. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to PGHL.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check PGHL.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, PGHL.BO has a market cap of 112.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while PGHL.BO trades at ₹6,783.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas PGHL.BO's P/E ratio is 37.58. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check PGHL.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check CAPPL.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, AKUMS.NS has a market cap of 103.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while AKUMS.NS trades at ₹665.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas AKUMS.NS's P/E ratio is 54.09. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to AKUMS.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check AKUMS.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SUDEEPPHRM.NS has a market cap of 96.9B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SUDEEPPHRM.NS trades at ₹863.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SUDEEPPHRM.NS's P/E ratio is 99.20. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SUDEEPPHRM.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, STAR.BO has a market cap of 96.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while STAR.BO trades at ₹1,052.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas STAR.BO's P/E ratio is 17.31. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to STAR.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check STAR.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, STAR.NS has a market cap of 96.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while STAR.NS trades at ₹1,050.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas STAR.NS's P/E ratio is 17.30. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to STAR.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check STAR.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SUVEN.NS has a market cap of 70.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SUVEN.NS trades at ₹297.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SUVEN.NS's P/E ratio is -25.84. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SUVEN.NS's ROE of -0.87%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SUVEN.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SUVEN.BO has a market cap of 70.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SUVEN.BO trades at ₹299.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SUVEN.BO's P/E ratio is -25.12. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SUVEN.BO's ROE of -0.87%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SUVEN.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SPARC.NS has a market cap of 69.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SPARC.NS trades at ₹212.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SPARC.NS's P/E ratio is 4.49. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SPARC.NS's ROE of +14.36%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SPARC.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SPARC.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SPARC.BO has a market cap of 69.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SPARC.BO trades at ₹211.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SPARC.BO's P/E ratio is 4.49. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SPARC.BO's ROE of +14.36%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SPARC.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SPARC.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, FDC.NS has a market cap of 67.9B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while FDC.NS trades at ₹416.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas FDC.NS's P/E ratio is 27.03. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to FDC.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check FDC.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, AARTIPHARM.BO has a market cap of 62.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while AARTIPHARM.BO trades at ₹683.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas AARTIPHARM.BO's P/E ratio is 33.09. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to AARTIPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check AARTIPHARM.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, AARTIPHARM.NS has a market cap of 62.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while AARTIPHARM.NS trades at ₹682.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas AARTIPHARM.NS's P/E ratio is 23.66. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to AARTIPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check AARTIPHARM.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SHILPAMED.BO has a market cap of 60.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SHILPAMED.BO trades at ₹609.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SHILPAMED.BO's P/E ratio is 49.87. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SHILPAMED.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SHILPAMED.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, INNOVACAP.NS has a market cap of 55.5B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while INNOVACAP.NS trades at ₹964.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas INNOVACAP.NS's P/E ratio is 45.62. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to INNOVACAP.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check INNOVACAP.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SEQUENT.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SEQUENT.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SEQUENT.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ORCHPHARMA.BO has a market cap of 50.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ORCHPHARMA.BO trades at ₹969.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ORCHPHARMA.BO's P/E ratio is 67.55. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ORCHPHARMA.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, ORCHPHARMA.NS has a market cap of 50.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while ORCHPHARMA.NS trades at ₹982.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas ORCHPHARMA.NS's P/E ratio is 159.35. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check ORCHPHARMA.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, BLISSGVS.NS has a market cap of 48.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while BLISSGVS.NS trades at ₹450.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas BLISSGVS.NS's P/E ratio is 38.12. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to BLISSGVS.NS's ROE of +0.11%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check BLISSGVS.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, BLISSGVS.BO has a market cap of 48.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while BLISSGVS.BO trades at ₹454.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas BLISSGVS.BO's P/E ratio is 38.26. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to BLISSGVS.BO's ROE of +0.11%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check BLISSGVS.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, RPGLIFE.BO has a market cap of 48.7B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while RPGLIFE.BO trades at ₹2,910.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas RPGLIFE.BO's P/E ratio is 41.91. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to RPGLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check RPGLIFE.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, RPGLIFE.NS has a market cap of 48.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while RPGLIFE.NS trades at ₹2,892.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas RPGLIFE.NS's P/E ratio is 42.05. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to RPGLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check RPGLIFE.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, IOLCP.BO has a market cap of 44.5B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while IOLCP.BO trades at ₹149.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas IOLCP.BO's P/E ratio is 29.75. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check IOLCP.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, IOLCP.NS has a market cap of 44.5B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while IOLCP.NS trades at ₹149.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas IOLCP.NS's P/E ratio is 29.81. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check IOLCP.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, NOVARTIND.NS has a market cap of 40.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while NOVARTIND.NS trades at ₹1,623.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas NOVARTIND.NS's P/E ratio is 42.44. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check NOVARTIND.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, NOVARTIND.BO has a market cap of 40.2B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while NOVARTIND.BO trades at ₹1,618.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas NOVARTIND.BO's P/E ratio is 42.39. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check NOVARTIND.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, GUJTHEM.NS has a market cap of 39.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while GUJTHEM.NS trades at ₹357.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas GUJTHEM.NS's P/E ratio is 83.90. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check GUJTHEM.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, GUFICBIO.NS has a market cap of 38.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while GUFICBIO.NS trades at ₹383.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas GUFICBIO.NS's P/E ratio is 59.73. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to GUFICBIO.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check GUFICBIO.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, GUFICBIO.BO has a market cap of 38.3B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while GUFICBIO.BO trades at ₹385.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas GUFICBIO.BO's P/E ratio is 59.62. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to GUFICBIO.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check GUFICBIO.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, UNICHEMLAB.BO has a market cap of 38.1B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while UNICHEMLAB.BO trades at ₹538.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas UNICHEMLAB.BO's P/E ratio is 15.13. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to UNICHEMLAB.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check UNICHEMLAB.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, UNICHEMLAB.NS has a market cap of 38B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while UNICHEMLAB.NS trades at ₹538.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas UNICHEMLAB.NS's P/E ratio is 15.04. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check UNICHEMLAB.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, AARTIDRUGS.NS has a market cap of 37.5B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while AARTIDRUGS.NS trades at ₹412.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas AARTIDRUGS.NS's P/E ratio is 19.34. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to AARTIDRUGS.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check AARTIDRUGS.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, AARTIDRUGS.BO has a market cap of 37.5B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while AARTIDRUGS.BO trades at ₹411.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas AARTIDRUGS.BO's P/E ratio is 19.34. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, WOCKPHARMA.BO is more volatile compared to AARTIDRUGS.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check AARTIDRUGS.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, MOREPENLAB.BO has a market cap of 31B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while MOREPENLAB.BO trades at ₹55.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas MOREPENLAB.BO's P/E ratio is 32.71. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check MOREPENLAB.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, MOREPENLAB.NS has a market cap of 31B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while MOREPENLAB.NS trades at ₹55.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas MOREPENLAB.NS's P/E ratio is 30.14. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check MOREPENLAB.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SOLARA.BO has a market cap of 24.5B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SOLARA.BO trades at ₹502.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SOLARA.BO's P/E ratio is 369.05. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SOLARA.BO's ROE of -0.00%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SOLARA.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SOLARA.BO's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, SOLARA.NS has a market cap of 24.4B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while SOLARA.NS trades at ₹500.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas SOLARA.NS's P/E ratio is 286.93. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to SOLARA.NS's ROE of -0.00%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to SOLARA.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check SOLARA.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, INDOCO.NS has a market cap of 22.9B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while INDOCO.NS trades at ₹244.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas INDOCO.NS's P/E ratio is -17.64. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to INDOCO.NS's ROE of -0.10%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to INDOCO.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check INDOCO.NS's competition here

Wockhardt Limited (BSE: WOCKPHARMA.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.BO stands at 303B. In comparison, INDOCO.BO has a market cap of 22.9B. Regarding current trading prices, WOCKPHARMA.BO is priced at ₹1,848.70 on the BSE, while INDOCO.BO trades at ₹244.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.BO currently has a P/E ratio of 142.29, whereas INDOCO.BO's P/E ratio is -23.82. In terms of profitability, WOCKPHARMA.BO's ROE is +0.04%, compared to INDOCO.BO's ROE of -0.10%. Regarding short-term risk, WOCKPHARMA.BO is less volatile compared to INDOCO.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.BO.Check INDOCO.BO's competition here